SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
5
#000000
#FFFFFF
Demonstrators protest pharmaceutical companies' lobbying outside Pharmaceutical Research and Manufacturers of America (PhRMA) headquarters in Washington, D.C. on September 21, 2021. (Photo: Saul Loeb/AFP via Getty Images)
'Enough Is Enough': Outrage as Big Pharma Hikes Prices on 442 Drugs
"Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
Jan 03, 2022
Patient advocates on Monday condemned the U.S. pharmaceutical industry for ushering in the new year with price hikes on more than 440 medications, a move that came as congressional Democrats' plan to lower prescription drug costs remained stuck due to Sen. Joe Manchin's persistent obstruction.
"Clearly, the need for drug pricing reform is as urgent as ever."
According to the healthcare firm GoodRx, the prices of 434 brand-name drugs and eight generic medicines were increased by an average of 5.2% and 4.2%, respectively, beginning on January 1, 2022.
The largest hike came courtesy of Pfizer, which raised the price of its anti-inflammatory medication Solu-Cortef by nearly 17%. The price boost took effect after Pfizer had a massively profitable 2021 thanks in large part to its coronavirus vaccine, which benefited from public funding and U.S. government-developed technology.
"At a time when Americans are struggling with the surging omicron variant and prices for prescription drugs that are four times what other wealthy nations pay, Big Pharma began the new year yet again hitting Americans with unjustified and widespread price hikes," David Mitchell, a cancer patient and founder of Patients for Affordable Drugs, said in a statement.
Mitchell said the price increases bolster findings of a nearly three-year House Oversight Committee probe showing that the pharmaceutical industry has "raised prices with abandon" and "manipulated the patent system" to prevent fairly priced generic competition.
"Clearly," said Mitchell, "the need for drug pricing reform is as urgent as ever--Americans are struggling to afford the medications they need and have waited too long for relief."
The Build Back Better Act, Democrats' flagship social spending and climate legislation, includes provisions that would allow Medicare to directly negotiate the prices of a limited subset of prescription drugs and penalize pharmaceutical companies that raise prices faster than the rate of inflation.
But the legislation--which the pharmaceutical industry spent big to water down and obstruct--is currently stalled in the evenly divided Senate thanks to Manchin, who is refusing to support the popular bill.
"He can't be the final word. Too much is at stake," Margarida Jorge, head of Lower Drug Prices Now, said in a statement last month after Manchin announced his opposition to the current version of the Build Back Better Act.
"The Senate must immediately find a way to lower drug prices in line with the framework agreed to by senators and the White House," Jorge added. "Families can't afford to wait."
According to a recent study conducted by the polling organization Gallup in partnership with the nonprofit West Health, roughly 15.5 million U.S. adults under the age of 65 and 2.3 million seniors were unable to afford at least one doctor-prescribed medication in 2021, a finding that bolstered calls for government action to rein in sky-high drug costs in the U.S.
A Government Accountability Office analysis released in April 2021 estimated that the U.S. pays two to four times more for prescription medications than other wealthy nations.
Mitchell said Monday that the drug pricing-related provisions of the Build Back Better Act would "directly take on Big Pharma's price gouging" and "deliver relief to patients" by capping out-of-pocket costs for Medicare Part D beneficiaries, among other changes.
"These reforms are overwhelmingly supported by more than 80% of voters--Democrats, Republicans, and Independents alike--and will fight inflation by holding the line on premiums and health care costs for patients, employers, employees, and taxpayers," Mitchell added. "Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
An Urgent Message From Our Co-Founder
Dear Common Dreams reader, It’s been nearly 30 years since I co-founded Common Dreams with my late wife, Lina Newhouser. We had the radical notion that journalism should serve the public good, not corporate profits. It was clear to us from the outset what it would take to build such a project. No paid advertisements. No corporate sponsors. No millionaire publisher telling us what to think or do. Many people said we wouldn't last a year, but we proved those doubters wrong. Together with a tremendous team of journalists and dedicated staff, we built an independent media outlet free from the constraints of profits and corporate control. Our mission has always been simple: To inform. To inspire. To ignite change for the common good. Building Common Dreams was not easy. Our survival was never guaranteed. When you take on the most powerful forces—Wall Street greed, fossil fuel industry destruction, Big Tech lobbyists, and uber-rich oligarchs who have spent billions upon billions rigging the economy and democracy in their favor—the only bulwark you have is supporters who believe in your work. But here’s the urgent message from me today. It's never been this bad out there. And it's never been this hard to keep us going. At the very moment Common Dreams is most needed, the threats we face are intensifying. We need your support now more than ever. We don't accept corporate advertising and never will. We don't have a paywall because we don't think people should be blocked from critical news based on their ability to pay. Everything we do is funded by the donations of readers like you. When everyone does the little they can afford, we are strong. But if that support retreats or dries up, so do we. Will you donate now to make sure Common Dreams not only survives but thrives? —Craig Brown, Co-founder |
Our work is licensed under Creative Commons (CC BY-NC-ND 3.0). Feel free to republish and share widely.
Patient advocates on Monday condemned the U.S. pharmaceutical industry for ushering in the new year with price hikes on more than 440 medications, a move that came as congressional Democrats' plan to lower prescription drug costs remained stuck due to Sen. Joe Manchin's persistent obstruction.
"Clearly, the need for drug pricing reform is as urgent as ever."
According to the healthcare firm GoodRx, the prices of 434 brand-name drugs and eight generic medicines were increased by an average of 5.2% and 4.2%, respectively, beginning on January 1, 2022.
The largest hike came courtesy of Pfizer, which raised the price of its anti-inflammatory medication Solu-Cortef by nearly 17%. The price boost took effect after Pfizer had a massively profitable 2021 thanks in large part to its coronavirus vaccine, which benefited from public funding and U.S. government-developed technology.
"At a time when Americans are struggling with the surging omicron variant and prices for prescription drugs that are four times what other wealthy nations pay, Big Pharma began the new year yet again hitting Americans with unjustified and widespread price hikes," David Mitchell, a cancer patient and founder of Patients for Affordable Drugs, said in a statement.
Mitchell said the price increases bolster findings of a nearly three-year House Oversight Committee probe showing that the pharmaceutical industry has "raised prices with abandon" and "manipulated the patent system" to prevent fairly priced generic competition.
"Clearly," said Mitchell, "the need for drug pricing reform is as urgent as ever--Americans are struggling to afford the medications they need and have waited too long for relief."
The Build Back Better Act, Democrats' flagship social spending and climate legislation, includes provisions that would allow Medicare to directly negotiate the prices of a limited subset of prescription drugs and penalize pharmaceutical companies that raise prices faster than the rate of inflation.
But the legislation--which the pharmaceutical industry spent big to water down and obstruct--is currently stalled in the evenly divided Senate thanks to Manchin, who is refusing to support the popular bill.
"He can't be the final word. Too much is at stake," Margarida Jorge, head of Lower Drug Prices Now, said in a statement last month after Manchin announced his opposition to the current version of the Build Back Better Act.
"The Senate must immediately find a way to lower drug prices in line with the framework agreed to by senators and the White House," Jorge added. "Families can't afford to wait."
According to a recent study conducted by the polling organization Gallup in partnership with the nonprofit West Health, roughly 15.5 million U.S. adults under the age of 65 and 2.3 million seniors were unable to afford at least one doctor-prescribed medication in 2021, a finding that bolstered calls for government action to rein in sky-high drug costs in the U.S.
A Government Accountability Office analysis released in April 2021 estimated that the U.S. pays two to four times more for prescription medications than other wealthy nations.
Mitchell said Monday that the drug pricing-related provisions of the Build Back Better Act would "directly take on Big Pharma's price gouging" and "deliver relief to patients" by capping out-of-pocket costs for Medicare Part D beneficiaries, among other changes.
"These reforms are overwhelmingly supported by more than 80% of voters--Democrats, Republicans, and Independents alike--and will fight inflation by holding the line on premiums and health care costs for patients, employers, employees, and taxpayers," Mitchell added. "Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
Patient advocates on Monday condemned the U.S. pharmaceutical industry for ushering in the new year with price hikes on more than 440 medications, a move that came as congressional Democrats' plan to lower prescription drug costs remained stuck due to Sen. Joe Manchin's persistent obstruction.
"Clearly, the need for drug pricing reform is as urgent as ever."
According to the healthcare firm GoodRx, the prices of 434 brand-name drugs and eight generic medicines were increased by an average of 5.2% and 4.2%, respectively, beginning on January 1, 2022.
The largest hike came courtesy of Pfizer, which raised the price of its anti-inflammatory medication Solu-Cortef by nearly 17%. The price boost took effect after Pfizer had a massively profitable 2021 thanks in large part to its coronavirus vaccine, which benefited from public funding and U.S. government-developed technology.
"At a time when Americans are struggling with the surging omicron variant and prices for prescription drugs that are four times what other wealthy nations pay, Big Pharma began the new year yet again hitting Americans with unjustified and widespread price hikes," David Mitchell, a cancer patient and founder of Patients for Affordable Drugs, said in a statement.
Mitchell said the price increases bolster findings of a nearly three-year House Oversight Committee probe showing that the pharmaceutical industry has "raised prices with abandon" and "manipulated the patent system" to prevent fairly priced generic competition.
"Clearly," said Mitchell, "the need for drug pricing reform is as urgent as ever--Americans are struggling to afford the medications they need and have waited too long for relief."
The Build Back Better Act, Democrats' flagship social spending and climate legislation, includes provisions that would allow Medicare to directly negotiate the prices of a limited subset of prescription drugs and penalize pharmaceutical companies that raise prices faster than the rate of inflation.
But the legislation--which the pharmaceutical industry spent big to water down and obstruct--is currently stalled in the evenly divided Senate thanks to Manchin, who is refusing to support the popular bill.
"He can't be the final word. Too much is at stake," Margarida Jorge, head of Lower Drug Prices Now, said in a statement last month after Manchin announced his opposition to the current version of the Build Back Better Act.
"The Senate must immediately find a way to lower drug prices in line with the framework agreed to by senators and the White House," Jorge added. "Families can't afford to wait."
According to a recent study conducted by the polling organization Gallup in partnership with the nonprofit West Health, roughly 15.5 million U.S. adults under the age of 65 and 2.3 million seniors were unable to afford at least one doctor-prescribed medication in 2021, a finding that bolstered calls for government action to rein in sky-high drug costs in the U.S.
A Government Accountability Office analysis released in April 2021 estimated that the U.S. pays two to four times more for prescription medications than other wealthy nations.
Mitchell said Monday that the drug pricing-related provisions of the Build Back Better Act would "directly take on Big Pharma's price gouging" and "deliver relief to patients" by capping out-of-pocket costs for Medicare Part D beneficiaries, among other changes.
"These reforms are overwhelmingly supported by more than 80% of voters--Democrats, Republicans, and Independents alike--and will fight inflation by holding the line on premiums and health care costs for patients, employers, employees, and taxpayers," Mitchell added. "Patients are counting on Congress and the Biden administration to deliver drug pricing reforms immediately in this new year."
We've had enough. The 1% own and operate the corporate media. They are doing everything they can to defend the status quo, squash dissent and protect the wealthy and the powerful. The Common Dreams media model is different. We cover the news that matters to the 99%. Our mission? To inform. To inspire. To ignite change for the common good. How? Nonprofit. Independent. Reader-supported. Free to read. Free to republish. Free to share. With no advertising. No paywalls. No selling of your data. Thousands of small donations fund our newsroom and allow us to continue publishing. Can you chip in? We can't do it without you. Thank you.